Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54

Ticagrelor reduced major adverse cardiovascular event (MACE) by 15-16% in patients with prior myocardial infarction (MI) in PEGASUS-TIMI 54. We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular bene...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European heart journal Ročník 37; číslo 14; s. 1133
Hlavní autoři:	Bonaca, Marc P, Bhatt, Deepak L, Steg, P Gabriel, Storey, Robert F, Cohen, Marc, Im, Kyungah, Oude Ophuis, Ton, Budaj, Andrej, Goto, Shinya, López-Sendón, José, Diaz, Rafael, Dalby, Anthony, Van de Werf, Frans, Ardissino, Diego, Montalescot, Gilles, Aylward, Philip, Magnani, Giulia, Jensen, Eva C, Held, Peter, Braunwald, Eugene, Sabatine, Marc S
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 07.04.2016
Témata:	Adenosine - administration & dosage Adenosine - adverse effects Adenosine - analogs & derivatives Aged Drug Administration Schedule Female Hemorrhage - chemically induced Humans Male Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - mortality Myocardial Ischemia - mortality Myocardial Ischemia - prevention & control Purinergic P2Y Receptor Antagonists - administration & dosage Purinergic P2Y Receptor Antagonists - adverse effects Risk Factors Secondary Prevention Treatment Outcome Antiplatelet therapy Secondary prevention P2Y12 inhibition Ischaemic risk Platelet inhibition Ticagrelor Coronary artery disease
ISSN:	1522-9645, 1522-9645
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!